Enlivex announces positive Phase I data for knee osteoarthritis trial, with potential novel treatment.

From GlobeNewswire: 2024-12-05 10:49:28

Enlivex Therapeutics announces positive interim efficacy data from Phase I of Allocetra™ trial for knee osteoarthritis, showing significant improvements in pain reduction and functionality. No serious adverse reactions reported during Phase I. Trial now enrolling patients for Phase II, a double-blind, randomized, placebo-controlled stage. Osteoarthritis affects over 32.5 million Americans, with no current drugs proven to reverse disease progression. Allocetra™ may provide a novel treatment alternative. Symptomatic knee osteoarthritis is prevalent, with 40% of men and 47% of women affected in their lifetimes. Enlivex is developing Allocetra™ to reprogram macrophages and rebalance the immune system.



Read more at GlobeNewswire: Enlivex Announces Positive Interim Efficacy Data from